{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:27:58Z","timestamp":1757586478377,"version":"3.41.2"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012028","name":"Netherlands Thrombosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organization for Health Research and Development","doi-asserted-by":"crossref","award":["10430012010004"],"award-info":[{"award-number":["10430012010004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002999","name":"Dutch Ministry of Health, Welfare and Sport","doi-asserted-by":"publisher","award":["329517"],"award-info":[{"award-number":["329517"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The first wave of COVID led to an alarmingly high mortality rate among nursing home residents (NHRs). In hospitalised patients, the use of anticoagulants may be associated with a favourable prognosis. However, it is unknown whether the use of antithrombotic medication also protected NHRs from COVID-19-related mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the effect of current antithrombotic therapy in NHRs with COVID-19 on 30-day all-cause mortality during the first COVID-19 wave.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective cohort study linking electronic health records and pharmacy data in NHRs with COVID-19. A propensity score was used to match NHRs with current use of therapeutic dose anticoagulants to NHRs not using anticoagulant medication. The primary outcome was 30-day all-cause mortality, which was evaluated using a logistic regression model. In a secondary analysis, multivariable logistic regression was performed in the complete study group to compare NHRs with current use of therapeutic dose anticoagulants and those with current use of antiplatelet therapy to those without such medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 3521 NHRs with COVID-19 based on a positive RT-PCR for SARS-CoV-2 or with a well-defined clinical suspicion of COVID-19. In the matched propensity score analysis, NHRs with current use of therapeutic dose anticoagulants had a significantly lower all-cause mortality (OR\u2009=\u20090.73; 95% CI: 0.58\u20130.92) compared to NHRs who did not use therapeutic anticoagulants. In the secondary analysis, current use of therapeutic dose anticoagulants (OR: 0.62; 95% CI: 0.48\u20130.82) and current use of antiplatelet therapy (OR 0.80; 95% CI: 0.64\u20130.99) were both associated with decreased mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>During the first COVID-19 wave, therapeutic anticoagulation and antiplatelet use were associated with a reduced risk of all-cause mortality in NHRs. Whether these potentially protective effects are maintained in vaccinated patients or patients with other COVID-19 variants, remains unknown.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ageing\/afae094","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:46:44Z","timestamp":1715784404000},"source":"Crossref","is-referenced-by-count":2,"title":["The effect of current antithrombotic therapy on mortality in nursing home residents with COVID-19: a multicentre retrospective cohort study"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4649-4988","authenticated-orcid":false,"given":"Firdaouss","family":"Boutkourt","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc , De Boelelaan 1117, Amsterdam ,","place":["The Netherlands"]},{"name":"Farmadam Pharmacy Group , Contactweg 127, Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thijs","family":"van Haaps","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC , location AMC Meibergdreef 9, Amsterdam ,","place":["The Netherlands"]},{"name":"Pulmonary Hypertension & Thrombosis, Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene\u00e9","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre+ , Maastricht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soerajja","family":"Bhoelan","sequence":"additional","affiliation":[{"name":"Department of Hematology , UMC Groningen, ,","place":["The Netherlands"]},{"name":"University of Groningen , UMC Groningen, ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre+ , Maastricht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke J H A","family":"Kruip","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Erasmus University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-2612","authenticated-orcid":false,"given":"Bart","family":"Spaetgens","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre+ , Maastricht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"van Es","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC , location AMC Meibergdreef 9, Amsterdam ,","place":["The Netherlands"]},{"name":"Pulmonary Hypertension & Thrombosis, Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tineke","family":"Roest","sequence":"additional","affiliation":[{"name":"Farmadam Pharmacy Group , Contactweg 127, Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlijn J","family":"Joling","sequence":"additional","affiliation":[{"name":"Amsterdam Public Health Research Institute , Amsterdam UMC, , Amsterdam, The Netherlands, Department of Medicine for Older People, Amsterdam UMC, Location VUmc, De Boelelaan 1117, Amsterdam ,","place":["The Netherlands"]},{"name":"VU University Medical Center , Amsterdam UMC, , Amsterdam, The Netherlands, Department of Medicine for Older People, Amsterdam UMC, Location VUmc, De Boelelaan 1117, Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Hematology , UMC Groningen, ,","place":["The Netherlands"]},{"name":"University of Groningen , UMC Groningen, ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Hugtenburg","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location VUmc , De Boelelaan 1117, Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024103110532977700_ref1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Middeldorp","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024103110532977700_ref2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"2024103110532977700_ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"key":"2024103110532977700_ref4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2024103110532977700_ref5","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial","volume":"325","author":"Investigators","year":"2021","journal-title":"JAMA"},{"key":"2024103110532977700_ref6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2024103110532977700_ref7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2024103110532977700_ref8","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"2024103110532977700_ref9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for Thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024103110532977700_ref10","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"2024103110532977700_ref11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/jama.2022.2361","article-title":"Thromboinflammation and antithrombotics in COVID-19: accumulating evidence and current status","volume":"327","author":"Connors","year":"2022","journal-title":"JAMA"},{"key":"2024103110532977700_ref12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jama.2021.23866","article-title":"Antiplatelet therapy in patients with COVID-19-more is less?","volume":"327","author":"Spaetgens","year":"2022","journal-title":"JAMA"},{"key":"2024103110532977700_ref13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/jgs.16664","article-title":"Mortality and the use of antithrombotic therapies among nursing home residents with COVID-19","volume":"68","author":"Brouns","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"2024103110532977700_ref14","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jamda.2020.10.034","article-title":"Clinical suspicion of COVID-19 in nursing home residents: symptoms and mortality risk factors","volume":"21","author":"Rutten","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2024103110532977700_ref15","article-title":"Mortality among care home residents in England during the first and second waves of the COVID-19 pandemic: an observational study of 4.3 million adults over the age of 65","volume":"14","author":"Schultze","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2024103110532977700_ref16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12877-021-02013-3","article-title":"Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes","volume":"21","author":"D'Ascanio","year":"2021","journal-title":"BMC Geriatr"},{"key":"2024103110532977700_ref17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","article-title":"Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis","volume":"99","author":"Zhou","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2024103110532977700_ref18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jamda.2013.02.003","article-title":"Incidence of venous thromboembolism in nursing home residents","volume":"14","author":"Reardon","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"2024103110532977700_ref19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jamda.2021.11.012","article-title":"Mortality reduction associated with coexistent antithrombotic use in nursing home residents with COVID-19","volume":"23","author":"Adler","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"2024103110532977700_ref20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jamda.2020.06.045","article-title":"The post-acute and long-term care crisis in the aftermath of COVID-19: a Dutch perspective","volume":"21","author":"Spaetgens","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2024103110532977700_ref21","article-title":"COVID-19 in nursing homes a study of diagnosis, symptomatology and disease course","volume":"164","author":"Rutten","year":"2020","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2024103110532977700_ref22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"Sturmer","year":"2014","journal-title":"J Intern Med"},{"key":"2024103110532977700_ref23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejim.2020.06.006","article-title":"Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era","volume":"77","author":"Rossi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2024103110532977700_ref24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijcard.2020.12.024","article-title":"Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study","volume":"329","author":"Denas","year":"2021","journal-title":"Int J Cardiol"},{"key":"2024103110532977700_ref25","doi-asserted-by":"crossref","DOI":"10.3390\/nu13010039","article-title":"Regular use of VKA prior to COVID-19 associated with lower 7-day survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID cohort study","volume":"13","author":"Menager","year":"2020","journal-title":"Nutrients"},{"key":"2024103110532977700_ref26","doi-asserted-by":"crossref","first-page":"e4039","DOI":"10.1093\/cid\/ciaa1258","article-title":"Reduced vitamin K status as a potentially modifiable risk factor of severe coronavirus disease 2019","volume":"73","author":"Dofferhoff","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/53\/5\/afae094\/60271973\/afae094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/53\/5\/afae094\/60271973\/afae094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T11:30:41Z","timestamp":1730374241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afae094\/7673531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afae094","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"type":"print","value":"0002-0729"},{"type":"electronic","value":"1468-2834"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,5,1]]},"article-number":"afae094"}}